Table 3.
Diagnostic Performances of All Methods for Predicting Liver Cirrhosis in the training and validation cohort
| Training (n = 144) | Validation (n = 150) | Training vs. Validation | |
|---|---|---|---|
| Methods | AUROC (95%CI) | AUROC (95%CI) | Delong test |
| Radiomics nomogram | 0.915 (0.869, 0.961) | 0.872 (0.814, 0.930) | P = .257 |
| CT-reported cirrhosis status | 0.752 (0.683, 0.821) | 0.755 (0.683, 0.827) | P = .961 |
| APRI | 0.725 (0.642, 0.809) | 0.731 (0.649, 0.814) | P = .921 |
| FIB-4 | 0.664 (0.575, 0.753) | 0.688 (0.601, 0.775) | P = .705 |
| Comparison of AUROC (Delong test) | |||
| Radiomics nomogram vs. CT-reported cirrhosis status | P < .001 | P = .006 | |
| Radiomics nomogram vs. APRI | P < .001 | P = .003 | |
| Radiomics nomogram vs. FIB-4 | P < .001 | P < .001 | |
| CT-reported cirrhosis status vs. APRI | P = .594 | P = .651 | |
| CT-reported cirrhosis status vs. FIB-4 | P = .073 | P = .201 | |
| APRI vs. FIB-4 | P = .040 | P = .040 | |
Note. ——Data in parentheses are the 95% confidence interval. APRI aspartate transaminase-to-platelet ratio index, AUROC area under the receiver operating characteristic, FIB-4 fibrosis-4